Would you use bevacizumab in a metastatic RAS-mutant colon cancer, if the patient had a colon perforation that was resected?

The risk for bevacizumab-related bowel perforation has been reported and evaluated in multiple studies. The absolute number is a quick low.

Here is one of the largest studies with 1,953 colorectal cancer patients who had bevacizumab treatment with median follow up of 20.1 months. Among the 1,953 pat...

Yes. That is not a contraindication.